Vaccination for COVID-19 control and considerations for Australia

Vaccines remain the main prospect for an exit strategy from COVID-19 pandemic, and may, depending on efficacy, duration of protection uptake, make herd immunity feasible. If is not achievable, SARS-COV-2 will circulate long-term. There are many vaccine candidates in development choices between vaccines that vary efficacy safety. The available compared ranges 62–95% against symptomatic infection with G614 variant. Efficacy reduced new variants concern uncertain asymptomatic infection. Some show a better protective immune response than natural principles prerequisites achieving it, such as coverage, discussed. alternative strategies including mass vaccination, targeted risk or age-based vaccination ring well speed reviewed. Finally, impact programs logistics